BioCryst Flu Treatment’s Success May Hinge On Government Contract
This article was originally published in The Pink Sheet Daily
Executive Summary
Rapivab (peramivir) is company’s first FDA approval, but market opportunity is small; some analysts predict firm will focus resources on hereditary angioedema development programs.